Lilly says Phase 3b ADtouch trial shows EBGLYSS beats placebo in hand and foot atopic dermatitis skin clearance at Week 16

• Eli Lilly reported Phase 3b ADtouch results for EBGLYSS in moderate-to-severe hand and foot atopic dermatitis.
• Late-breaking data will be presented at the EADV Congress running Sept. 30–Oct. 3 in Vienna.
• Treatment met key study goals, showing rapid skin clearing with meaningful relief in itch and pain versus placebo.
• Patient-reported satisfaction improved, supporting a broader value story beyond clinician-assessed skin outcomes.
• Lilly has submitted the findings to the FDA to support a potential label update for localized hand and foot disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE60006) on September 30, 2026, and is solely responsible for the information contained therein.